Asymchem Laboratories (Tianjin) Co., Ltd. 002821.SZ

CN · XSHE · XSHE · stock · Healthcare · website

Asymchem Laboratories (Tianjin) Co., Ltd. financials (annual)

Revenue

Net income

Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥6.7B	CN¥5.8B	CN¥7.8B	CN¥10.3B
Gross profit	CN¥2.8B	CN¥2.5B	CN¥4.0B	CN¥4.9B
R&D expense	CN¥593.3M	CN¥614.5M	CN¥707.9M	CN¥708.9M
SG&A expense	CN¥260.9M	CN¥309.7M	CN¥335.5M	CN¥286.8M
Operating income	CN¥1.3B	CN¥702.3M	CN¥2.3B	CN¥3.2B
Interest expense	CN¥12.8M	CN¥9.5M	CN¥5.9M	CN¥10.5M
Income tax	CN¥159.7M	CN¥136.6M	CN¥306.3M	CN¥430.3M
Net income	CN¥1.1B	CN¥949.0M	CN¥2.3B	CN¥3.3B
EPS (diluted)	CN¥3.16	CN¥2.69	CN¥6.26	CN¥9.00
Operating cash flow	CN¥1.4B	CN¥1.3B	CN¥3.5B	CN¥3.3B
Free cash flow	CN¥137.2M	CN¥124.3M	CN¥2.3B	CN¥1.1B
Cash & equivalents	CN¥6.3B	CN¥5.8B	CN¥7.1B	CN¥5.3B
Inventory	CN¥1.5B	CN¥1.2B	CN¥945.3M	CN¥1.5B
Goodwill	CN¥146.2M	CN¥146.2M	CN¥146.2M	CN¥146.2M
Total assets	CN¥20.3B	CN¥19.3B	CN¥19.8B	CN¥18.2B
Total debt	CN¥309.2M	CN¥324.8M	CN¥147.2M	CN¥138.3M
Total liabilities	CN¥2.6B	CN¥2.4B	CN¥2.3B	CN¥2.5B
Shareholders' equity	CN¥17.6B	CN¥16.8B	CN¥17.5B	CN¥15.6B

Growth · year-over-year · Revenue CAGR -13.4%

Metric	FY2025	FY2024	FY2023	FY2022
Revenue growth	+14.9%	-25.8%	-23.7%	—
Net income growth	+19.3%	-58.2%	-31.3%	—
EPS growth	+17.5%	-57.0%	-30.4%	—
Free cash flow growth	+10.4%	-94.6%	+103.1%	—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.